Buy Heavy! This is How I Found the Next 158% Stock
Published: 2025-08-19
Status:
Analyzed
Published: 2025-08-19
Status:
Analyzed
Predictions from this Video
Incorrect: 0
Prediction
Topic
Status
Novo Nordisk (NVO) stock price predicted to rebound to $140 per share, representing 169% upside from its current level.
"What I'm going to show you here could be just the beginning of a rebound back to last year's $140 per share would be 169% upside"
Pending
Novo Nordisk's oral GLP-1 drug application is predicted to be approved by the FDA, making it the first pill form for weight loss drugs on the market.
"If it is approved, and it is the first application that that has been accepted uh by the FDA, if it is approved, it'll be the first pill form for these weight loss drugs out on the market."
Pending
Novo Nordisk (NVO) stock is predicted to reach a $90 per share price target, representing a 70% return, based on a rerating to a 7x price to sales multiple.
"I do think it gets there... a $90 per share price target on shares of Novo Nordisk... you get that rerating to seven times price to sales."
Pending
Hims & Hers (HIM) stock is predicted to first experience a sell-off due to the crackdown on compounded drugs, then rebound with a price jump once it stops selling them and potentially renews its partnership with Novo Nordisk.
"I do think shares of him and hers eventually rebounds on some of that news. But first, it's likely to see a sell-off on the crackdown to compounds... once him and hers finally stops selling these compounds or stops making these compounds available on his platform, that brings Novo Nordisk back in for this deal and the price jumps again. But I think you have to wait for that to happen."
Pending
Compounded generic GLP-1 drugs are predicted to face restrictions and begin to be removed from the market.
"So there are going to be restrictions on these compounds and they're going to start coming off of the market."
Pending
The US President is predicted to implement pharmaceutical tariffs over many years through a step-rate process, which will benefit companies with existing US manufacturing facilities like Eli Lilly.
"when the president does start his does start leaning into his pharmaceuticals tariffs that he's talking about. It's going to be happen over many years and it's going to be a step rate in the tariff but it's going to it's going to benefit companies that already have that US manufacturing in place which uh obviously Eli Lilly has much much better"
Pending
Novo Nordisk stock (NVO) is predicted to rebound to its 2024 high of $140 per share, representing 169% upside.
"could be just the beginning of a rebound back to last year's $140 per share would be 169% upside"
Pending
Novo Nordisk's GLP-1 pill application is predicted to be approved by the FDA, making it the first pill-form weight loss drug on the market.
"If it is approved, and it is the first application that that has been accepted uh by the FDA, if it is approved, it'll be the first pill form for these weight loss drugs out on the market."
Pending
Novo Nordisk's 2025 sales growth forecast (currently 8-14%) is predicted to be upgraded due to increased restrictions on compounded drugs, the release of the pill form, and new indications for Wegovy.
"I do believe that with the uh with the compound restrictions with the pill form coming out as well as just with more indications being approved for Reggoi like we saw with that fatty liver disease I believe this is going to be upgraded"
Pending
Novo Nordisk (NVO) stock is predicted to reach $90 per share.
"about a $90 per share price target on shares of Novo Nordisk. I do think it gets there."
Pending
Hims & Hers (HIM) stock is predicted to first sell off due to a crackdown on compounded drugs, then eventually rebound.
"I do think shares of him and hers eventually rebounds on some of that news. But first, it's likely to see a sell-off on the crackdown to compounds."
Pending
New US pharmaceutical tariffs, introduced by the president over many years with a step rate, are predicted to benefit companies with US manufacturing, such as Eli Lilly (LLY).
"when the president does start his does start leaning into his pharmaceuticals tariffs that he's talking about. It's going to be happen over many years and it's going to be a step rate in the tariff but it's going to it's going to benefit companies that already have that US manufacturing in place which uh obviously Eli Lilly has much much better"
Pending
Compounded GLP-1 generic drugs are predicted to face increasing restrictions and begin to be removed from the market.
"So there are going to be restrictions on these compounds and they're going to start coming off of the market."
Pending